Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
gptkb:drug
|
| gptkbp:approves |
gptkb:2012
multiple countries |
| gptkbp:availability |
generic versions available
|
| gptkbp:class |
gptkb:drug
antidiabetic agent |
| gptkbp:clinical_trial |
Phase III
as monotherapy showed reduced risk of hospitalization for heart failure in combination with other antidiabetic medications showed improved glycemic control showed renal protective effects |
| gptkbp:contraindication |
end-stage renal disease
severe renal impairment hypersensitivity to dapagliflozin |
| gptkbp:dosage_form |
10 mg
5 mg |
| gptkbp:education |
importance of hydration
monitoring for infections adherence to prescribed regimen recognizing symptoms of low blood sugar |
| gptkbp:formulation |
gptkb:tablet
|
| gptkbp:has_ability |
may cause weight loss
|
| https://www.w3.org/2000/01/rdf-schema#label |
Forxiga
|
| gptkbp:ingredients |
gptkb:dapagliflozin
|
| gptkbp:is_affected_by |
may improve kidney function
|
| gptkbp:is_used_for |
treatment of type 2 diabetes
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:market |
ongoing studies
|
| gptkbp:marketed_as |
Farxiga in the US
|
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver absorbed in the gastrointestinal tract |
| gptkbp:population |
adults with type 2 diabetes
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
recommended in diabetes management guidelines
|
| gptkbp:regulatory_compliance |
prescription only
|
| gptkbp:research_focus |
long-term safety
renal outcomes cardiovascular outcomes |
| gptkbp:side_effect |
dehydration
hypoglycemia urinary tract infections genital infections may lower blood pressure may reduce cardiovascular risk |
| gptkbp:treatment |
with insulin
with metformin with sulfonylureas |
| gptkbp:type_of_care |
once daily dosing
|
| gptkbp:bfsParent |
gptkb:Dapagliflozin
|
| gptkbp:bfsLayer |
4
|